Prevalence and patient-rated relevance of complexity factors in medication regimens of community-dwelling patients with polypharmacy.
Adherence
Medication administration
Medication regimen complexity
Patient-centered care
Polypharmacy
Shared decision-making
Journal
European journal of clinical pharmacology
ISSN: 1432-1041
Titre abrégé: Eur J Clin Pharmacol
Pays: Germany
ID NLM: 1256165
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
14
12
2021
accepted:
14
03
2022
pubmed:
28
4
2022
medline:
14
6
2022
entrez:
27
4
2022
Statut:
ppublish
Résumé
To describe the prevalence of complexity factors in the medication regimens of community-dwelling patients with more than five drugs and to evaluate the relevance of these factors for individual patients. Data were derived from the HIOPP-6 trial, a controlled study conducted in 9 general practices which evaluated an electronic tool to detect and reduce complexity of drug treatment. The prevalence of complexity factors was based on the results of the automated analysis of 139 patients' medication data. The relevance assessment was based on the patients' rating of each factor in an interview (48 patients included for analysis). A median of 5 (range 0-21) complexity factors per medication regimen were detected and at least one factor was observed in 131 of 139 patients. Almost half of these patients found no complexity factor in their medication regimen relevant. In most medication regimens, complexity factors could be identified automatically, yet less than 15% of factors were indeed relevant for patients as judged by themselves. When assessing complexity of medication regimens, one should especially consider factors that are both particularly frequent and often challenging for patients, such as use of inhalers or tablet splitting. The HIOPP-6 trial was registered retrospectively on May 17, 2021, in the German Clinical Trials register under DRKS-ID DRKS00025257.
Identifiants
pubmed: 35476124
doi: 10.1007/s00228-022-03314-1
pii: 10.1007/s00228-022-03314-1
pmc: PMC9184426
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1127-1136Subventions
Organisme : Innovation Fund of The Federal Joint Committee
ID : 01VSF16019
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Diabetes Res Clin Pract. 2017 Aug;130:34-42
pubmed: 28554141
Rev Esp Quimioter. 2021 Apr;34(2):93-99
pubmed: 33499583
Ann Pharmacother. 2014 Jun 17;48(9):1129-1137
pubmed: 24939633
Respir Med. 2014 Jul;108(7):992-8
pubmed: 24873874
Drug Saf. 2013 Jan;36(1):31-41
pubmed: 23315294
Eur J Clin Pharmacol. 2020 Jun;76(6):745-754
pubmed: 32239242
J Am Geriatr Soc. 2017 Apr;65(4):747-753
pubmed: 27991653
J Clin Med. 2021 Mar 06;10(5):
pubmed: 33800845
Eur J Clin Pharmacol. 2013 Apr;69(4):937-48
pubmed: 23052416
Eur J Clin Pharmacol. 2007 Dec;63(12):1203-4
pubmed: 17899044
Consult Pharm. 2018 Sep 1;33(9):484-496
pubmed: 30185289
Ann Pharmacother. 2004 Sep;38(9):1369-76
pubmed: 15266038
Pharmacoepidemiol Drug Saf. 2014 Oct;23(10):1088-92
pubmed: 24648258
Int J Clin Pharm. 2013 Dec;35(6):1130-6
pubmed: 23963541
Expert Opin Drug Saf. 2013 Nov;12(6):829-40
pubmed: 23984969
NPJ Prim Care Respir Med. 2017 Apr 3;27(1):22
pubmed: 28373682
BMC Med Inform Decis Mak. 2020 Jul 8;20(1):154
pubmed: 32641027
Consult Pharm. 2012 May;27(5):341-52
pubmed: 22591978
Lancet. 2017 Mar 11;389(10073):1055-1065
pubmed: 28290995
Pharmaceutics. 2019 Apr 09;11(4):
pubmed: 30970554
Ann Pharmacother. 2016 Feb;50(2):89-95
pubmed: 26681444
J Manag Care Pharm. 2013 Jun;19(5):396-407
pubmed: 23697477
Ann Pharmacother. 2020 Apr;54(4):301-313
pubmed: 31718244
Ann Pharmacother. 2018 Nov;52(11):1117-1134
pubmed: 29756471
Patient Prefer Adherence. 2020 Nov 02;14:2135-2145
pubmed: 33173282